Principal Financial Group
FDMT icon

Principal Financial Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Principal Financial Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-21,034
Closed -$442K – 2291
2024
Q2 		$442K Buy
21,034
+1,849
+10% +$46.4K ﹤0.01% 1984
2024
Q1 		$611K Buy
19,185
+9,204
+92% +$235K ﹤0.01% 1944
2023
Q4 		$202K Sell
9,981
-1,060
-10% -$13.9K ﹤0.01% 2168
2023
Q3 		$141K Buy
+11,041
New +$185K ﹤0.01% 2219

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Principal Financial Group's FDMT Position: Q3 2024 in Review

Principal Financial Group sold out of 4D Molecular Therapeutics (FDMT) in Q3 2024, closing a stake of 21,034 shares — an estimated $442K sold.

Principal Financial Group first reported a position in FDMT in Q3 2023 and held it in 4 quarters. The position peaked at $611K in Q1 2024. 140 funds tracked by Wall St. Rank hold FDMT as of Q3 2024.

  • Principal Financial Group reported no remaining 4D Molecular Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 21,034 4D Molecular Therapeutics shares in Q3 2024, an estimated $442K.
  • Principal Financial Group first reported a position in 4D Molecular Therapeutics in Q3 2023 and held it in 4 quarters.
  • Principal Financial Group's 4D Molecular Therapeutics position peaked at $611K in Q1 2024.
  • 140 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.